Matrix metalloproteinase-9 level and gene polymorphism in sleep disordered breathing patients with or without cardiovascular disorders
Matrix metalloproteinase-9 level and gene polymorphism in sleep disordered breathing patients with or without cardiovascular disorders
Objective: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. We aimed to investigate the matrix metalloproteinase-9 (MMP-9) level and MMP-9 gene polymorphism in sleep apnea patients with or without cardiovascular disease. Study Design: Case-control study. Material and Methods: Two hundred nine patients [Mean age (±SD), 47 (±12) yrs; M/F, 170/39] diagnosed with sleep-disordered breathing were included in the study. Serum MMP-9 level was performed using enzyme-linked immunosorbant assay (ELISA) and MMP-9 gene polymorphism with polymerase chain reaction-restriction fragment length polymorphism. We divided the patient group into two subgroups: (1) patients with confirmed cardiovascular disease, i.e. CV-P Group and (2) patients without cardiovascular disease, CV-N Group. We compared all parameters between the two groups. Results: There were 56 OSAS patients with cardiovascular disorder (CV-positive group) and 153 OSAS patients without cardiovascular disorder (CV- negative group). CC, CT and TT genotype distributions between groups were similar [31 (55%), 25 (45%), 0 (0%) vs 88 (57%), 61 (40%), 4 (3%); respectively, p>0.05]. MMP-9 level was significantly higher in CV-P patients (442.7±139.3 pg/mL) than in CV-N patients (364.4±165.0 pg/mL; p=0.0018). Conclusion: Our results showed that the presence of MMP-9 polymorphism was not associated with cardiovascular disease. MMP-9 level was higher in OSAS patients with cardiovascular disorders than without cardiovascular disorders. Finally, MMP-9 genotype was not associated with serum MMP-9 levels.
___
- 1. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al. Sleep-disordered breathing and cardiovascular dis- ease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25.
- 2. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased in- cidence of cardiovascular disease in middle-aged men with ob- structive sleep-apnea: a 7-year follow up. Am J Respir Crit Care Med 2002;166:159-65. [CrossRef]
- 3. Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001;164:2147-65.
- 4. Brauer PR. MMPs role in cardiovascular development and dis- ease. Front Biosci 2006;11:447-78. [CrossRef]
- 5. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Saw- yer DB, et al. Regulations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004;109:2850-6. [CrossRef]
- 6. Ye S. Influence of matrix metalloproteinase genotype on car- diovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-45. [CrossRef]
- 7. Wang L, Zhu T, Li Y. Relationship between matrix metalloprotein- ase-9 polymorphism and acute coronary syndrome. Journal of Nanjing Medical University 2007;21:147-50. [CrossRef]
- 8. Tazaki T, Minoguchi K, Yokoe T, Samson KT, Minoguchi H, Tanaka A, et al. Increased levels and activity of matrix metalloprotein- ase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2011;170:1354-9. [CrossRef]
- 9. Ye J, Liu H, Li Y, Liu X, Zhu J. Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep ap- nea syndrome. Chin Med J 2007;120:1482-6.
- 10. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2005;365:183-7. [CrossRef]
- 11. The Report of American Academy of Sleep Medicine. Task Force Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;5:667-89.
- 12. Rechtschaffen A, Kales A (1968). A Manual of Standardized Ter- minology, Technique, and Scoring System for Sleep Stages of Hu- man Subjects, BIS/ BRI, UCLA, Los Angeles.
- 13. Öztürk L, Mansour B, Yüksel M, Yalçın AS, Çelikoğlu F, Gökhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep apnea patient. Clin Chim Acta 2003;332:83-8. [CrossRef]
- 14. Gremlich S, Nguyen D, Reymondin D, Hohlfeld P, Vial Y, Wit- kin SS, et al. Fetal MMP2/MMP9 polymorphisms and intrauter- ine growth restriction risk. J Reprod Immunol 2007;74:143-51. [CrossRef]
- 15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Haf- ner D, et al. Plasma concentration and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascu- lar disease. Circulation 2003;107:1579-85. [CrossRef]
- 16. Kaditis AG, Alexopoulos EI, Karathanasi A, Ntamagka G, Oikonomidi S, Kiropoulos TS, et al. Adiposity and low grade systemic inflamma- tion modulate matrix metalloproteinase-9 levels in Greek children with sleep apnea. Pediatr Pulmonol 2010;45:693-9. [CrossRef]
- 17. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gela- tinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-94. [CrossRef]
- 18. Opstad TB, Pettersen AAR, Weiss TW, Akra S, Ovstebo R, Arne- sen H, et al. Genetic variation, gene expression and circulating levels of matrix metalloproteinase-9 in patients with stable coro- nary artery disease. Clin Chim Acta 2012;413:113-20. [CrossRef]
- 19. Alp E, Menevse S, Tulmac M, Kan D, Yalcin R, Erkan AF, et al. Lack of association between matrix metalloproteinase-9 and endothe- lial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol 2009;28:343-50. [CrossRef]
- 20. Pöllanen PJ, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttila AM, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloprotein- ase 9 gene: An autopsy study. Arterioscler Thromb Vasc Biol 2001;21:1446-50. [CrossRef]
- 21. Volna J, Kemlink D, Kalousova M, Vavrova J, Majerova V, Mestek O, et al. Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. Med Sci Monit 2011;17:CR491-7. [CrossRef]
- 22. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of ex- cessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6. [CrossRef]
- 23. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selec- tively induce expression of 92-kDa gelatinase by human macro- phages. J Immunol 1996;157:4159-65.